MDxHealth S.A. (MDXH)
$0.66+10.00%Close
SELLRECOVERY · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $34M
- Beta
- 0.38
- P/E (TTM)
- -1.12
- Short % float
- 3.28%
- Days to cover
- 5.4
- SI change
- -11.5%
- 1W
- +10.00%
- 1M
- -7.04%
- vs SPY 1W
- +10.14%
- vs SPY 1M
- -9.55%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 11
- VALUE
- 13
- GROWTH
- 29
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC85.6%
REV YoY-
ROE142.6%
EPS YoY-
ROA-22.9%
GROSS58
OP-20
NET-37
[VALUATION]
P/E TTM-1.12
P/E FWD-
SECTOR PE20.34
INDUSTRY PE31.41
P/B-1.14
P/FCF-
EV/EBITDA-15.56
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO1.15
ND/EBITDA-
BETA0.38
Company news
FAQ
- What is LOPJLB’s current signal on MDXH?
- LOPJLB’s latest quantitative signal on MDxHealth S.A. (MDXH) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is MDXH in?
- MDxHealth S.A. (MDXH) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does MDxHealth S.A. (MDXH) do?
- MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive u…